Vibrio vulnificus Infections From a Previously Nonendemic Area

Ann Intern Med. 2019 Oct 1;171(7):520-521. doi: 10.7326/L19-0133. Epub 2019 Jun 18.

Authors

Madeline King¹, Lucia Rose², Henry Fraimow², Maria Nagori³, Mobeen Danish², Katherine Doktor²

Affiliations

¹ University of the Sciences, Philadelphia, Pennsylvania (M.K.).
² Cooper University Hospital, Camden, New Jersey (L.R., H.F., M.D., K.D.).
³ Geisinger Health System, Scranton, Pennsylvania (M.N.).

PMID: 31207614
DOI: 10.7326/L19-0133

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Animals
Anti-Bacterial Agents / therapeutic use
Bays
Brachyura / microbiology*
Ceftriaxone / therapeutic use
Diabetes Mellitus, Type 2
Doxycycline / therapeutic use
Drug Therapy, Combination
Hepatitis B
Humans
Male
Mid-Atlantic Region
Middle Aged
Occupational Exposure / adverse effects
Recreation
Restaurants
Shellfish / microbiology*
Tigecycline / therapeutic use
Vibrio Infections / diagnosis*
Vibrio Infections / drug therapy

Substances

Anti-Bacterial Agents
Tigecycline
Ceftriaxone
Doxycycline

Supplementary concepts

Vibrio vulnificus infection